| Literature DB >> 30064375 |
S Inés Lozano-Ramos1,2, Ioana Bancu3,4, Laura Carreras-Planella1,2, Marta Monguió-Tortajada1,2, Laura Cañas3,4, Javier Juega3,4, Josep Bonet3,4, M Pilar Armengol5, Ricardo Lauzurica4, Francesc E Borràs6,7,8.
Abstract
BACKGROUND: Kidney transplantation (KTx) is the best therapeutic approach for chronic kidney diseases leading to irreversible kidney failure. Considering the origin of the graft, several studies have reported differences between living (LD) and deceased donors (DD) in graft and patient survival. These differences seem to be related to multiple factors including, donor age and time of cold ischemia among others. Many of transplanted organs come from old-aged DDs, in which pre-transplant biopsy is recommended. However, kidney biopsy has several limitations, and there is a need to develop alternatives to assess the status of a kidney before transplantation. As the analysis of urinary extracellular vesicles (uEVs) rendered promising results as non-invasive biomarkers of kidney-related pathologies, this pilot study aimed to investigate whether profiling uEVs of LDs and DDs may be of help to assess the quality of the kidney before nephrectomy.Entities:
Keywords: Exosomes; Extracellular vesicles; Kidney donor; Kidney transplantation; Size-exclusion chromatography
Mesh:
Substances:
Year: 2018 PMID: 30064375 PMCID: PMC6069839 DOI: 10.1186/s12882-018-0985-3
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Clinical and Epidemiological characteristics of living and deceased donors
| uEV Analysis | Age | Gender | HTA | DM2 | DLP | Others | SrCr (mg/dL) | Remuzzi Score | Cause of death | Drugs | ICU Drugs | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RK | LK | ||||||||||||
| LD1 | P,T | 40–45 | F | – | – | – | – | 0.7 | – | – | – | – | – |
| LD2 | P,T | 55–60 | F | – | – | – | – | 0.98 | – | – | – | – | – |
| LD3 | P,T | 65–70 | M | – | – | – | – | 0.63 | – | – | – | – | – |
| LD4 | P,T | 50–55 | M | – | – | Yes | Hipotirodism | 0.93 | – | – | – | simvastatin, Levotiroxine | – |
| LD5 | P,T | 55–60 | F | – | – | – | – | 1.02 | – | – | – | – | – |
| DD1 | P, T | 65–70 | F | Yes | – | Yes | – | 0.8 | 3 | 3 | CVA | Olmesartan, Lormetazepam | noradrenaline, furosemide |
| DD2 | P, T | 65–70 | F | – | Yes | – | obesity | 0.8 | 5 | 5 | Ictus | metformine, insuline | clopidogrelt, amoxiciline-clavulanic |
| DD3 | P,T | 80–85 | F | Yes | – | Yes | – | 1.5 | 4 | 5 | CVA | bisoprolol,torasemide, lorazepam, sertralin, simvastatin | – |
| DD4 | T | 75–80 | M | Yes | Yes | Yes | – | 1.8 | 4 | 4 | Trauma | Triflusal;enalapril; Metformin; Gliclazide; Ezetimibe; Allopurinol; Glucosamine; Tenoxicam; Omeprazole | manitol, actocortine, noradrenaline, |
| DD5 | T | 55–60 | M | Yes | – | – | – | 1.56 | 2 | – | Cardiac event | Losartan, Atorvastatin, fenofibrate | propofol, atropine, midazolam, noradrenaline |
| DD6 | P | 45–50 | M | – | – | – | Bone cyst | 3.41 | 2 | 2 | PTE | oxcarbazepine, diazepam, Celecoxib. | adrenaline |
| DD7 | P | 70–75 | F | – | – | Yes | osteoporosis | 0.73 | 3 | 2 | Ictus | Calcium | noradrenaline |
A summary of the age, gender, diseases, cause of death and medication of all the patients is included in this Table. P: sample used for proteomic assays. T: sample used for NGS assays
F female, M male; HTA Hypertension, DM2 Diabetes Mellitus type 2, DLP Dyslipemia, CVA cerebrovascular accident, PTE Pulmonary thrombo-embolism, SrCr Serum Creatinine, RK right kidney, LK left kidney
Sample characterization
| Living donor | Deceased Donor | |
|---|---|---|
| Urine samples | ||
| Kidneys available for KTx | ||
| Kidneys transplanted | ||
| Functional organs (1 year after KTx) |
Sample size details from urine sample collection to recipients outcome
Clinical characteristics of kidney receptors
| Donor | uEV Analysis | Cold ischemia (hours) | Mismatch | Recipient’s previous KTx | DSA | IS | Delay Graft function | ACR | CHR | KB | Days until stable Renal function | SrCr (mg/dL) 1 year After KTx | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | DR | ||||||||||||
| LD1 | P, T | 2 | 0 | 0 | 0 | 1 | – | P, B, FK, MMf | – | – | – | – | 5 | 1 |
| LD2 | P, T | 2 | 1 | 1 | 1 | – | – | P, B, FK, MMf | – | – | – | – | 6 | 1.2 |
| LD3 | P, T | 2 | 1 | 1 | 2 | – | – | P, B, FK, MMf | – | – | – | – | 8 | 1.14 |
| LD4 | P, T | 2 | 1 | 1 | 1 | – | – | P, B, FK, MMf | Yes | Yes | – | ACR | – | – |
| LD5 | P, T | 4 | 1 | 2 | 1 | – | – | P, B, FK, MMf | ||||||
| DD1 | P, T | 20 | 2 | 2 | 1 | – | – | P, FK, MMf | – | – | – | – | 14 | 1,82 |
| Not transplanted | ||||||||||||||
| DD2 | P,T | 18 | 2 | 2 | 1 | – | – | P, B, FK, MMf | – | – | – | – | 20 | 1.77 |
| 22 | 0 | 0 | 1 | – | – | P, B, FK, MMf | – | – | – | – | 15 | 1.23 | ||
| DD3 | P,T | 18 | 1 | 1 | 1 | – | – | P, FK, Th, Everolimus | – | – | – | – | 7 | 1.45 |
| Not transplanted | ||||||||||||||
| DD4 | T | 20 | 1 | 1 | 1 | – | – | P, B, FK, MMf | – | – | – | CNTI | 15 | 1.67 |
| 15 | 1 | 2 | 1 | – | – | P, B, FK, MMf | – | – | – | ATN, TAIF | 6 | 2.6 | ||
| DD5 | T | 20 | 1 | 2 | 2 | – | – | P, B, FK, MMf | – | – | – | – | 9 | 1.64 |
| 17 | 1 | 1 | 1 | – | – | Eculizumab, P, FK, MMF, Th | – | – | – | – | 24 | 1.39 | ||
| DD6 | P | 13 | 2 | 2 | 1 | – | – | P, B, FK, MMf | – | Yes | – | ACR | 24 | 1.03 |
| 22 | 1 | 1 | 1 | – | Yes | P,FK; MMf, Th | – | – | – | – | 25 | 1.16 | ||
| DD7 | P | 17 | 2 | 2 | 1 | – | – | P, B, FK, MMf | Yes | – | – | – | 30 | 1.01 |
| 20 | 1 | 1 | 1 | – | – | P, B, FK, MMf | – | – | – | – | 30 | 1.01 | ||
A summary of the HLA-mismatch, donor specific antibodies (DSA), cold ischemia time, previous transplants, immunosuppression treatment, delay graft function and renal biopsy are provided. P: sample used for proteomic assays. T: sample used for transcriptomic NGS assays
KTx Kidney transplantation, DSA donor specific antibodies, IS immunosuppression treatment, ACR acute cellular rejection, CHR chronic humoral rejection, KB kidney biopsy, P Prednisone, FK Tacrolimus, MMf mycophenolate mofetil, B Basiliximab, Th Thymoglobulin, ATN Acute tubular necrosis, CNIT calcineurin inhibitor toxicity, TAIF tubular atrophy and interstitial fibrosis, AS arteriosclerosis
Fig. 1Representative elution profile of uEVs by size-exclusion chromatography (SEC). The expression of CD63 and CD9, depicted as the median fluorescence intensity (MFI, left axis), indicates uEVs presence in SEC fractions. Isotype control is depicted by a dotted line. The total protein content (mg/ml; right axis) was measured in each SEC fraction
Fig. 2Representative profile of Small RNA from uEVs isolated by size-exclusion chromatography. Total RNA extracted from pooled uEVs profiled by small RNA gel electrophoresis showed a main peak at 60 nucleotides (P3) and a minor peak of RNA around 10–40 nucleotides (P2). The lower marker of the small RNA kit can be observed at 4 nucleotides (P1). A representative experiment is shown
Fig. 3miRNA analysis of uEV from living and deceased donor. a Venn diagrams showing the shared and differential miRNA content in uEVs from LD (n = 5) and DD (n = 5) detected by next generation sequencing. 205 miRNAs overlap amongst the different samples analysed of LD and DD. Only the miRNAs shared within all donors of each group were taken for analysis. b Hierarchical clustering analysis of LD and DD uEV samples. Differential analysis of the miRNA content of uEVs from LD and DD. c Scatter plot analysis of miRNAs found in uEVs from LD and DD. Dot plot representing the -log of the p-value and the difference between the miRNA expression of LD and DD groups. Interestingly, only one miRNA was identified as statistically over-represented in LD (in bold, p < 0.05)
miRNAs found by size-exclusion chromatography not described in vesicle-specific databases
| miRNA ID | |
|---|---|
| hsa-miR-7977 | |
| hsa-miR-1260a | |
| hsa-miR-210-5p | |
| hsa-miR-653-5p | |
| hsa-miR-3605-3p | |
| hsa-miR-203a-3p | |
| hsa-miR-888-5p | |
| hsa-miR-152-3p | |
| hsa-miR-874-3p | |
| hsa-miR-598-3p |
miRNAs found by size-exclusion chromatography and shared between LDs and DDs (n = 205) were compared with those reported in specific databases (EVpedia, Exocarta and Vesiclepedia). Those miRNAs not previously reported in EVs databases are listed
Fig. 4Protein analysis uEV from living and deceased donor by LC/MS-MS. Venn diagrams showing the overlap of proteins detected in uEVs from LD (a) and DD (b). c Hierarchical clustering analysis according to the protein content of uEVs from LD and DD. The analysis did not segregate samples in their corresponding group. d Scatter dot plot analysis of the protein content of uEVs from LD and DD. Scatter plot representing the -log of the p-value and the differences between LD and DD group